Supernus Pharmaceuticals, Inc. (SUPN)
NASDAQ: SUPN · Real-Time Price · USD
35.43
-0.34 (-0.95%)
Dec 20, 2024, 4:00 PM EST - Market closed
Supernus Pharmaceuticals Employees
Supernus Pharmaceuticals had 652 employees as of December 31, 2023. The number of employees increased by 40 or 6.54% compared to the previous year.
Employees
652
Change (1Y)
40
Growth (1Y)
6.54%
Revenue / Employee
$999,957
Profits / Employee
$91,583
Market Cap
1.96B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
PACS Group | 32,433 |
Alignment Healthcare | 1,536 |
LeMaitre Vascular | 630 |
Wave Life Sciences | 268 |
Mirum Pharmaceuticals | 264 |
Harmony Biosciences Holdings | 246 |
Tarsus Pharmaceuticals | 244 |
Akero Therapeutics | 56 |
SUPN News
- 5 days ago - Knight Therapeutics Announces Filing of New Drug Submission for Qelbree® (viloxazine) in Canada - GlobeNewsWire
- 25 days ago - Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Supernus Pharmaceuticals: Recently Launched Qelbree Is Powering Growth - Seeking Alpha
- 6 weeks ago - Supernus Pharmaceuticals, Inc. (SUPN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 7 weeks ago - Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024 - GlobeNewsWire
- 2 months ago - Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder - GlobeNewsWire